{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T01:52:13Z","timestamp":1795139533752,"version":"4.10.3"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,22]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors, particularly programmed cell death protein 1 (PD-1) blockers, have transformed cancer therapy but can induce immune-related endocrine toxicities. Severe involvement of multiple endocrine axes, including dual pituitary dysfunction, is rare and challenging to diagnose due to nonspecific clinical features. Highlighting such cases can improve early recognition and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 56-year-old man with esophageal cancer developed fatigue, polyuria, polydipsia, dizziness, and severe hyponatremia after treatment with tislelizumab, a PD-1 inhibitor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Laboratory evaluation revealed new-onset autoimmune diabetes, hypothyroidism, and secondary adrenal insufficiency. The constellation of biochemical abnormalities and clinical features, in the absence of alternative etiologies, indicated immune-related hypophysitis and pancreatic islet injury. Two additional cases of severe, recurrent hyponatremia after PD-1 therapy were also reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient received targeted hormone replacement therapy, including glucocorticoids and levothyroxine, along with insulin for glycemic control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Symptoms improved significantly, and biochemical parameters normalized following treatment, demonstrating effective management of multi-glandular endocrine failure induced by PD-1 blockade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>PD-1 inhibitors can cause severe, concurrent dysfunction of multiple endocrine organs. Clinicians should maintain high vigilance, implement proactive screening for pituitary and metabolic abnormalities during and after immune checkpoint inhibitor therapy, and adopt a multidisciplinary approach to ensure timely diagnosis and treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048449","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T17:00:24Z","timestamp":1779469224000},"page":"e48449","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Multiple endocrine adverse reactions and pituitary axis dysfunction induced by PD-1 immunotherapy in an esophageal cancer patient: Case report"],"prefix":"10.1097","volume":"105","author":[{"given":"Pei","family":"Sheng","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelin","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China"},{"name":"The First School of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xie","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mianhua","family":"Wu","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China"},{"name":"Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1877-4067","authenticated-orcid":false,"given":"Xiaofei","family":"An","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260707","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors.","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"R2-20260707","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4103\/ijmr.IJMR_313_19","article-title":"The side effects of immune checkpoint inhibitor therapy on the endocrine system.","volume":"154","author":"Goyal","year":"2021","journal-title":"Indian J Med Res"},{"key":"R3-20260707","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ijc.32132","article-title":"A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors.","volume":"145","author":"Arnaud-Coffin","year":"2019","journal-title":"Int J Cancer"},{"key":"R4-20260707","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors.","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"R5-20260707","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab.","volume":"101","author":"De Filette","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R6-20260707","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1210\/jc.2019-00423","article-title":"Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes.","volume":"104","author":"Tsang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R7-20260707","doi-asserted-by":"crossref","first-page":"e000591","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes.","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"key":"R8-20260707","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis.","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"R9-20260707","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update.","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"R10-20260707","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma.","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R11-20260707","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints.","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"R12-20260707","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes.","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"R13-20260707","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R14-20260707","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10\u2009mg\/kg versus ipilimumab 3\u2009mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"R15-20260707","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"R16-20260707","doi-asserted-by":"crossref","first-page":"e011865","DOI":"10.1136\/jitc-2025-011865","article-title":"Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.","volume":"13","author":"Zhu","year":"2025","journal-title":"J ImmunoTher Cancer"},{"key":"R17-20260707","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment.","volume":"14","author":"Di Dalmazi","year":"2019","journal-title":"Expert Rev Endocrinol Metab"},{"key":"R18-20260707","doi-asserted-by":"crossref","first-page":"101668","DOI":"10.1016\/j.beem.2022.101668","article-title":"Immune checkpoint inhibitor-related hypophysitis.","volume":"36","author":"Mizukoshi","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R19-20260707","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"R20-20260707","doi-asserted-by":"crossref","first-page":"e000779","DOI":"10.1136\/jitc-2020-000779","article-title":"Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study.","volume":"8","author":"Kobayashi","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"R21-20260707","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2169\/internalmedicine.9074-17","article-title":"Isolated adrenocorticotropin deficiency due to nivolumab-induced hypophysitis in a patient with advanced lung adenocarcinoma: a case report and literature review.","volume":"57","author":"Ohara","year":"2018","journal-title":"Intern Med"},{"key":"R22-20260707","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/js.2017-00414","article-title":"Two cases of atezolizumab-induced hypophysitis.","volume":"2","author":"Kanie","year":"2018","journal-title":"J Endocr Soc"},{"key":"R23-20260707","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41574-020-00437-2","article-title":"Insights into non-classic and emerging causes of hypopituitarism.","volume":"17","author":"Prodam","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"R24-20260707","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/jim-2021-002099","article-title":"Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort.","volume":"70","author":"Kotwal","year":"2022","journal-title":"J Investig Med"},{"key":"R25-20260707","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/ERC-20-0513","article-title":"Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns.","volume":"28","author":"Nguyen","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"R26-20260707","doi-asserted-by":"crossref","first-page":"281","DOI":"10.6004\/jnccn.2022.7098","article-title":"Hypophysitis and secondary adrenal insufficiency from immune checkpoint inhibitors: diagnostic challenges and link with survival.","volume":"21","author":"Johnson","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"R27-20260707","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series.","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"key":"R28-20260707","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12902-021-00854-y","article-title":"Late-onset hypophysitis after discontinuation of nivolumab treatment for advanced skin melanoma: a case report.","volume":"21","author":"Antoniou","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"R29-20260707","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12902-019-0335-x","article-title":"Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report.","volume":"19","author":"Takeno","year":"2019","journal-title":"BMC Endocr Disord"},{"key":"R30-20260707","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma.","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"R31-20260707","doi-asserted-by":"crossref","first-page":"e1911519","DOI":"10.1001\/jamanetworkopen.2019.11519","article-title":"Variation in the assessment of immune-related adverse event occurrence, grade, and timing in patients receiving immune checkpoint inhibitors.","volume":"2","author":"Hsiehchen","year":"2019","journal-title":"JAMA Netw Open"},{"key":"R32-20260707","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2013.52.2219","article-title":"Adverse event reporting in cancer clinical trial publications.","volume":"32","author":"Sivendran","year":"2014","journal-title":"J Clin Oncol"},{"key":"R33-20260707","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/annonc\/mdv182","article-title":"A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors.","volume":"26","author":"Chen","year":"2015","journal-title":"Ann Oncol"},{"key":"R34-20260707","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1507\/endocrj.EJ20-0436","article-title":"Anti-pituitary antibodies as a marker of autoimmunity in pituitary glands.","volume":"67","author":"Iwama","year":"2020","journal-title":"Endocr J"},{"key":"R35-20260707","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle.","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"R36-20260707","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejca.2020.02.049","article-title":"Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency.","volume":"130","author":"Yano","year":"2020","journal-title":"Eur J Cancer"},{"key":"R37-20260707","doi-asserted-by":"crossref","first-page":"e002493","DOI":"10.1136\/jitc-2021-002493","article-title":"Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors.","volume":"9","author":"Kobayashi","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"R38-20260707","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.3390\/cancers13164036","article-title":"Hypothalamic-pituitary autoimmunity in patients treated with anti-PD-1 and anti-PD-L1 antibodies.","volume":"13","author":"Bellastella","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R39-20260707","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.","volume":"5","author":"Puzanov","year":"2017","journal-title":"J ImmunoTher Cancer"},{"key":"R40-20260707","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline.","volume":"101","author":"Fleseriu","year":"2016","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:00:14Z","timestamp":1783414814000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":40,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048449","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"2025-06-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}